By Heather Blumenthal Think of chimeric antigen receptor (CAR T) therapy as the little girl from the nursery rhyme with a little curl right in the middle of her forehead – when she was good, she was very, very good, but when she was bad, she was horrid. CAR T therapy, when… Read more »
Category: News
Where Are They Now: Julian Smazynski
At BioCanRx, we are incredibly proud of our HQP and their dedication to cancer immunotherapy research. Whether they are working on viruses in the lab or examining the socioeconomic barriers to adopting certain treatments in Canada, each one plays a unique role in strengthening our network and expertise in immunotherapy. BioCanRx is invested in… Read more »
Another made-in-Canada CAR-T trial based on Canadian manufacturing capability
By Heather Blumenthal Over its lifetime, BioCanRx has funded important research into immunotherapy, helping to make a promising new avenue for cancer treatment a reality for Canadians whose cancer has not responded to other treatments. An equally important part of its work, however, has been developing the infrastructure needed to provide manufacturing and testing… Read more »
One small step for blood cancer patients, one giant step for Canadian cancer patients of all stripes
By Heather Blumenthal Ostensibly, it’s a clinical trial of an immunotherapy for blood cancer patients with specific kinds of leukemia or lymphoma, for whom other treatments have not been successful. A good result could mean the difference between life and death for these patients; the importance of this trial for them cannot be overstated,… Read more »
Where Are They Now: Alyssa Vito
At BioCanRx, we are incredibly proud of our HQP and their dedication to cancer immunotherapy research. Whether they are working on viruses in the lab or examining the socioeconomic barriers to adopting certain treatments in Canada, each one plays a unique role in strengthening our network and expertise in immunotherapy. BioCanRx is invested in… Read more »
Carl H. June to be Keynote Speaker at 2021 Summit4CI!
BioCanRx is pleased to announce Dr. Carl H. June as our distinguished keynote speaker for the 2022 Summit for Cancer Immunotherapy (Summit4CI) taking place November 19-21, 2022. Dr. June is the Richard W. Vague Professor in Immunotherapy, Director of the Center for Cellular Immunotherapies and Director of the Parker Institute for Cancer Immunotherapy… Read more »
Where Are They Now: James Han
At BioCanRx, we are incredibly proud of our HQP and their dedication to cancer immunotherapy research. Whether they are working on viruses in the lab or examining the socioeconomic barriers to adopting certain treatments in Canada, each one plays a unique role in strengthening our network and expertise in immunotherapy. BioCanRx is invested in… Read more »
International Day of Women & Girls in Science 2022: Words of Wisdom
BioCanRx, Canada’s Immunotherapy Network, is joining the global campaign to recognize the UN’s International Day of Women and Girls in Science. This international day is all about supporting and promoting the access of women and girls and their participation in science, technology, engineering and mathematics education, training, and research activities at all levels,… Read more »
World Cancer Day Message
February 4, 2022 Dr. John Bell, Scientific Director and Dr. Stéphanie Michaud, President & CEO BioCanRx Access to life-saving cancer diagnosis and treatment should be equitable for all. Yet there is an equity gap that is costing lives. Today is World Cancer Day – a global effort to unite the world’s population in… Read more »
Learning Institute Community Dissemination Report 2021
The BioCanRx-Cancer Stakeholder Alliance Learning Institute went virtual for the first time ever as part of Summit4CI 2021. This year, HQP and patient representatives engaged via Zoom to discuss and engage on the scientific content of the conference. The participants are happy to share the results of these conversations via their Community Dissemination Report,… Read more »
